38458074|t|In vitro evaluation of [3H]PI-2620 and structural derivatives in non-Alzheimer's tauopathies.
38458074|a|Alzheimer's disease (AD) and non-AD tauopathies such as chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) are characterized by the abnormal aggregation of three-repeat (3R) and/or four-repeat (4R) tau isoforms. Several tau-PET tracers have been applied for human imaging of AD and non-AD tauopathies including [18F]PI-2620. Our objective is to evaluate [3H]PI-2620 and two promising structural derivatives, [3H]PI-2014 and [3H]F-4, using in vitro saturation assays and competitive binding assays against new chemical entities based on this scaffold in human AD tissues for comparison with PSP, CBD and CTE tissues. Thin section autoradiography was employed to assess specific binding and distribution of [3H]PI-2620 and [3H]F-4 in fresh-frozen human post-mortem AD, PSP, CBD and CTE tissues. Immunohistochemistry was performed for phospho-tau (AT8) and 4R-tau (RD4). Homogenate filtration binding assays were performed for saturation analysis and competitive binding studies against [3H]PI-2620. All compounds bound with high affinity in AD tissue. In PSP tissue [3H]PI-2620 demonstrated the highest affinity (5.3 nM) and in CBD tissue [3H]F-4 bound with the highest affinity (9.4 nM). Over 40 fluorinated derivatives based on PI-2620 and F-4 were screened in AD and PSP tissue. Notably, compound 2 was the most potent derivative in PSP tissue (Ki = 7.3 nM). By autoradiography, [3H]PI-2620 and [3H]F-4 demonstrated positive signals similar in intensity in AD, PSP and CTE tissues that were displaced by homologous blockade. Binding of both radiotracers aligned with immunostaining for 4R-tau. This work demonstrates that [3H]PI-2620 and [3H]F-4 show promise for imaging 4R-tau aggregates in non-AD tauopathies. PI-2620 continues to serve as a structural scaffold for PET radiotracers with higher affinity for non-AD tau over AD tau.
38458074	23	34	[3H]PI-2620	Chemical	-
38458074	69	92	Alzheimer's tauopathies	Disease	MESH:D024801
38458074	94	113	Alzheimer's disease	Disease	MESH:D000544
38458074	115	117	AD	Disease	MESH:D000544
38458074	127	141	AD tauopathies	Disease	MESH:D024801
38458074	150	182	chronic traumatic encephalopathy	Disease	MESH:D000070627
38458074	184	187	CTE	Disease	MESH:D000070627
38458074	190	220	progressive supranuclear palsy	Disease	MESH:D013494
38458074	222	225	PSP	Disease	MESH:D013494
38458074	232	257	corticobasal degeneration	Disease	MESH:D000088282
38458074	259	262	CBD	Disease	MESH:D000088282
38458074	351	353	4R	Chemical	-
38458074	355	358	tau	Gene	4137
38458074	377	380	tau	Gene	4137
38458074	415	420	human	Species	9606
38458074	432	434	AD	Disease	MESH:D000544
38458074	443	457	AD tauopathies	Disease	MESH:D024801
38458074	468	480	[18F]PI-2620	Chemical	MESH:C000710692
38458074	511	522	[3H]PI-2620	Chemical	-
38458074	565	576	[3H]PI-2014	Chemical	-
38458074	581	588	[3H]F-4	Chemical	-
38458074	710	715	human	Species	9606
38458074	716	718	AD	Disease	MESH:D000544
38458074	747	750	PSP	Disease	MESH:D013494
38458074	752	755	CBD	Disease	MESH:D000088282
38458074	760	763	CTE	Disease	MESH:D000070627
38458074	862	873	[3H]PI-2620	Chemical	-
38458074	878	885	[3H]F-4	Chemical	-
38458074	902	907	human	Species	9606
38458074	920	922	AD	Disease	MESH:D000544
38458074	924	927	PSP	Disease	MESH:D013494
38458074	929	932	CBD	Disease	MESH:D000088282
38458074	937	940	CTE	Disease	MESH:D000070627
38458074	1141	1152	[3H]PI-2620	Chemical	-
38458074	1196	1198	AD	Disease	MESH:D000544
38458074	1210	1213	PSP	Disease	MESH:D013494
38458074	1221	1232	[3H]PI-2620	Chemical	-
38458074	1283	1286	CBD	Disease	MESH:D000088282
38458074	1294	1301	[3H]F-4	Chemical	-
38458074	1385	1392	PI-2620	Chemical	MESH:C000722249
38458074	1397	1400	F-4	Chemical	MESH:C006011
38458074	1418	1420	AD	Disease	MESH:D000544
38458074	1425	1428	PSP	Disease	MESH:D013494
38458074	1491	1494	PSP	Disease	MESH:D013494
38458074	1537	1548	[3H]PI-2620	Chemical	-
38458074	1553	1560	[3H]F-4	Chemical	-
38458074	1615	1617	AD	Disease	MESH:D000544
38458074	1619	1622	PSP	Disease	MESH:D013494
38458074	1627	1630	CTE	Disease	MESH:D000070627
38458074	1780	1791	[3H]PI-2620	Chemical	-
38458074	1796	1803	[3H]F-4	Chemical	-
38458074	1854	1868	AD tauopathies	Disease	MESH:D024801
38458074	1870	1877	PI-2620	Chemical	MESH:C000722249
38458074	1972	1974	AD	Disease	MESH:D000544
38458074	1975	1978	tau	Gene	4137
38458074	1984	1986	AD	Disease	MESH:D000544
38458074	1987	1990	tau	Gene	4137
38458074	Association	MESH:D000544	4137
38458074	Association	MESH:D000088282	4137
38458074	Negative_Correlation	MESH:C006011	MESH:D013494
38458074	Negative_Correlation	MESH:C000722249	MESH:D000544
38458074	Negative_Correlation	MESH:C006011	MESH:D000544
38458074	Association	MESH:C000710692	4137
38458074	Association	MESH:D024801	4137
38458074	Association	MESH:C000710692	MESH:D024801
38458074	Negative_Correlation	MESH:C000722249	MESH:D013494
38458074	Association	MESH:D013494	4137
38458074	Association	MESH:D000070627	4137

